Not every GLP-1 drug works in the same way for every patient: and not every patient sees the weight loss they were hoping for
This therapy is often sought out by individuals dealing with chronic inflammation, slow recovery from injuries or surgery, and persistent joint pain
It is not appropriate during pregnancy or breastfeeding, in active cancer, or in patients with severely uncontrolled metabolic disease without specialist coordination
Therefore, we used GLP-1RA as an exposure factor, and Cis-eQTL summary data (chromosome: 6
Merlin J, Ivanov S, Dumont A, Sergushichev A, Gall J, Stunault M, et al
Some GLP-1 medications have demonstrated cardiovascular benefits in clinical trials (such as LEADER for liraglutide, SUSTAIN-6 for semaglutide, and REWIND for dulaglutide), and discontinuation may result in loss of these protective effects